ImmunityBio leverages a persistent BCG shortage and expanding Anktiva use in NMIBC, with 2026 catalysts including FDA talks, global launches and new clinical milestones.
Zacks Investment Research on MSN
ImmunityBio stock soars 295% YTD: Time to buy, hold or sell?
Shares of ImmunityBio IBRX have skyrocketed nearly 300% year to date, significantly outperforming the industry’s 6% growth. The stock has outperformed the sector and the S&P 500 during the same period ...
Boston Consulting Group (BCG) and OpenAI today announced a multiyear expansion of their partnership with Frontier Alliance to continue to help organizations move beyond experimentation and accelerate ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
OpenAI’s new Frontier Alliances with Accenture, BCG, Capgemini, and McKinsey aim to speed enterprise agent deployments and AI strategy work.
The bacillus Calmette-Guérin (BCG) vaccine failed to protect against COVID-19 and other respiratory tract infections (RTIs) among older adults with comorbidities, according to a randomized trial from ...
Middle Eastern mergers and acquisitions (M&A) demonstrated remarkable resilience and strategic focus in 2025, with deal values surging 260 per cent to $53bn in the first nine months of the year ...
At the Global Cybersecurity Forum (GCF) 2025 in Riyadh, Boston Consulting Group and GCF unveiled The Quantum Leap: Navigating the Future of Computing, a comprehensive study examining how quantum ...
Intravesical immunotherapy in the form of BCG is the only effective adjuvant therapy for high-risk NMIBC (non-muscle-invasive bladder cancer) that reduces progression of disease Response to salvage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results